Leveraging Med Device Expertise to Develop Combination Products

Similar documents
Combination Products Verification, Validation & Human Factors Sept. 12, 2017

Medical Electronics I S O. Member of Amalthea Group. Switzerland

Model Based Design Of Medical Devices

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy

Implementing Quality Systems

Building Quality into Medical Device Documentation and Impact of New Device Regulation (Context: Inhaled Drug Devices) v4

INTEGRATING HUMAN FACTORS AND USABILITY TESTING INTO MEDICAL DEVICE RISK MANAGEMENT

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

4/8/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

FDA Centers of Excellence in Regulatory and Information Sciences

Leader in Pharmaceutical Films

Pre-clinical Development Support Services

Connecting People, Science and Regulation

Bringing Technology and Product Development Best Practices Together for Successful Innovation

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH. Notice to Industry Letters

Software as a Medical Device (SaMD)

New Approaches to Safety and Risk Management

J. Lawrence Stevens, RAC 833 E. Rosedale Dr. East Alton, IL (office) (mobile)

Coatings technology overview

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Vice President, Regulatory Affairs, Clinical Research, and Quality Assurance AREAS OF EXPERTISE

CDRH INNOVATION INITIATIVE. February 2011 Center for Devices and Radiological Health U.S. Food and Drug Administration

the SPD company Dr Clive Simon, Principal, The SPD Company.

Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development

Intellectual Property, Vaccine Production and Technology Transfer

National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs

peace of mind For from development to commercial supply

National Coordinated Registry Network (CRN) Think-tank

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

Patent (novel, non-obvious and useful) vs. Innovate Yes - we CAN do both! The 2015 ASQ Innovation Conference September 19-20

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson

FDA REGULATION OF DIGITAL HEALTH

ADVANCED PLASTICS. CBRN DEFENSE SYSTEMS

Claudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group

Pharmaceutical Manufacturing and Engineering Catalog Excerpt

Learning from real world use

Importance of ICH Guidance in Fulfilling Process Validation Requirements

Before I talk through the strategy itself, I want to tell you more about why

Navigating the Healthcare Innovation Cycle

Office of Pharmaceutical Quality: Why, What, and How?

Value Paper. Are you PAT and QbD Ready? Get up to speed

Medical Robotics LBR Med

Do not copy BME Abbreviated Course Title (19 spaces or less): Design of Biomedical Systems and Devices

Taking a broader view

Progressive Licensing and the Modernization of the Canadian Regulatory Framework

CDRH PMA Critical to Quality (CtQ) Pilot

The Medical Device Regulation: Transitioning between old and new

GE Healthcare. Vivid S5. Cardiovascular ultrasound system

AMERICAN MADE. experience INNOVATION. We are American Made

Innovation Progress and Future Outlook

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

2008 Course Programs Schedule

Global Harmonization Task Force

CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals

Piloting MDevSPICE - the Medical Device Software Process Assessment Framework

Deciding When to Submit a 510(k) for a Software Change to an Existing Device Draft Guidance for Industry and Food and Drug Administration Staff

TABLE OF CONTENTS DUPONT TYVEK MEDICAL PACKAGING TRANSITION PROJECT (MPTP) EXECUTIVE SUMMARY JUNE 2016 THE FINAL PHASE EXECUTIVE SUMMARY 2

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

Parallel Prototyping and the Engineer s Dilemma

Technical Documentation - Key pit falls

AUTO INJECTORS & PEN INJECTORS: A USER-CENTRIC DESIGN APPROACH

Medical Devices for the IoT Design Challenges Tilo Borchardt

ICH Q10 Pharmaceutical Quality System

of Temperatures and other Physical Parameters

JUST SCRATCHING THE SERVICE

Mike Hess Vice President, Innovation Medtronic Inc

USP Research & Innovation Program

YOUR INJECTION MOLDING PARTNER

J.P. Morgan Healthcare Conference Summary Transcript

2. Evidence themes and their importance along the development path

Moving from R&D to Manufacture

In the heart of Industrial electronics

Digital Medical Device Innovation: A Prescription for Business and IT Success

Medicines Manufacturing in the UK 2017

Quality by Design, Clinical Relevance & Lifecycle Considerations

Epilogue. Simona Rocchi Erasmus University, Centre for Environmental Studies, Rotterdam

February 5, 2010 VIA ELECTRONIC SUBMISSION

Driving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif

The Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process

STRATEGIC FRAMEWORK Updated August 2017

WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT!

WHO WE ARE MISSION STATEMENT

Guidance for Industry and FDA Staff Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use

HealthTech: What does it mean for compliance?

Clinical Forum Attendee Sample Job Titles

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

Conformity assessment procedures for hip, knee and shoulder total joint replacements

MEDICAL FROM TO FINISH. Product Design Capabilities

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003

Guidance for Industry

Fresenius Medical Care North America (FMCNA)

Vivid S5. Cardiovascular ultrasound system. GE Healthcare. Davis Medical

Microwave and Microelectronics

TECHNOLOGY. In hospitals the authority to make decisions DECISION MAKING

NEWS RELEASE. Life sciences companies tout their expertise in India

Draft Plan of Action Chair's Text Status 3 May 2008

The FDA: Merging Innovation and Opportunity to Impact Public Health

HARNESSING TECHNOLOGY

Global Perspectives on Clinical Engineering Trends Yadin David, Ed.D., P.E., C.C.E., FAACE, FAIMBE

Transcription:

Leveraging Med Device Expertise to Develop Combination Products 20 th Annual Drug Delivery Partnership Conference January 20, 2016 Dirk Smith VP of Technology Solutions Minnetronix, Inc.

250 employees, 20 years in business 100+ engineers with over 1.5M development hours on complex electromechanical medical devices, including drug delivery devices FDA-registered, ISO 13485 Certified Our medical device background: Development partner Med device manufacturer Technology developer

Minnetronix Experience with Combination Products Ultrasound nebulizer Design for manufacturability, test development and scale-up Photodynamic drug therapy light source Ground up design, concurrent with drug research Iontophoresis stimulator Next generation design and manufacturing Anesthesia delivery via battery-power device Multiple drug infusion pumps and systems Development of large volume and ambulatory pumps Insulin, chemotherapy and TPN applications

The Combination Product Development Paradigm From Early Development Considerations for Innovative Combination Products Guidance (FDA Office of Combination Products): When combining products such as drugs or biologics and devices that are customarily delivered using different regulatory paradigms, certain critical development issues, such as the interaction of the drug/biologic and device constituents, may not be readily apparent.

The Combination Product Development Paradigm Drug/Biologic Constituent Development cycles Pre-clinical/clinical testing Drug safety & compliance Device Constituent Design controls Usability / human factors Device safety & compliance Combination Product Drug/device interactions Clinical / Validation approach - IND or IDE Approval path (CBER, CDER, CDRH) System risk management - safety & efficacy Balanced/comprehensive QMS

Combination Product Resources Office of Combination Products: www.fda.gov/combinationproducts FDA Guidance Documents 01/2015 Current GMP Requirements for Combination Products 06/2011 Classification of Products as Drugs and Devices and Additional Product Classification Issues 04/2011 How to Write a Request for Designation 09/2006 Early Development Considerations for Innovative Combination Products Additional Work on the Challenges of Combination Products Articles, websites, courses, books, etc

The Device Constituent Perspective A Shared Mission Bringing new therapies to patients & clinicians with a Different Frame of Reference Development Cross-functional teams and technologies Time and Cost months and 7 figures($) Manufacturing High complexity, low-to-moderate volumes Anticipated product evolution Regulatory Process 510(k)/PMA Limited clinical trials w/small sample sizes

Complex Medical Device Regulatory Landscape Quality Systems QSR - 21 CFR Part 820 ISO 13485 Device Master Records & Design History Files Design controls - planning, requirements, design, verification & validation, risk management (ISO 14971), change management Compliance EN60601, Safety of Medical Electrical Equipment Software - IEC 62304 Usability and Human Factors - IEC 62366 EMC & Wireless, compliance and licenses Sterilization and biocompatibility

Challenges Unique to Device Development Complex, multi-technology systems and teams Multiple, concurrent engineering efforts Manufacturing, supply chain, quality & regulatory Third-party testing/certification/compliance DFM and scale-up Designing and building the first one is the easy part.. System testing, development through production How to test a combination product Critical requirements and essential performance Process validation Technology evolution Availability and obsolescence Leveraging new technology and balancing risk

Critical Combination Product Success Factors: The Device Partner Should Bring. Design through Manufacturing Expertise Proven design controls Experienced/professional/technical project managers DFx ( Design for Success mentality & processes) Prototyping & NPI Flexible, efficient manufacturing capabilities (Lean, SS, integration w/design)

Critical Combination Product Success Factors: The Device Partner Should Bring. A Positive Regulatory & Compliance Track Record Comprehensive quality system Successful FDA and ISO audit history Proactive standards and guidance document knowledge Regulatory submission experience & expertise

Critical Combination Product Success Factors: The Device Partner Should Bring. A relevant portfolio of products & technologies Applicable technologies for complex electromechanical devices Microfluidics Miniaturized pump and fluid control systems Safety critical software for life sustaining systems Wireless, implantable power and communications Track record of getting to the clinic

An Effective Device Partner will. Mitigate your device risks - technology/quality/reliability/ usability/safety/compliance/etc Bring knowledge and expertise - gained from an established track record of relevant technology & products Partner with you to manage the complex, cross-functional & concurrent demands of combination product development Prioritize critical business objectives and constraints bring a market appreciation with a systems perspective

Minnetronix A Unique Resource for Combination Product Commercialization Medical Device Systems Innovators Systems engineering and integration Software, hardware, electronic, and electromechanical design Valuable Technology for Better Outcomes Accelerating time to market and reducing development risk Creating market-focused solutions to maximize product value Providing Strategic Options Offering new types of engagements and partnerships Creating tailored strategies such as co-development ventures, spin-outs, or Newcos Developing new therapy solutions to unmet clinical needs

Questions and Discussion www.minnetronix.com Saint Paul, MN USA 651 917-4060